XERS Q2 2024 Earnings — Xeris Biopharma Holdings, Inc. Revenue & Financial Results | Market Cap Arena

XERSXeris Biopharma Holdings, Inc.

$960M

Q2 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$48M+26.5% YoY

Gross Profit

$38M78.2% margin

Operating Income

-$8M-17.0% margin

Net Income

-$15M-31.2% margin

EPS (Diluted)

$-0.10

QoQ Revenue Growth

+18.3%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$11M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$332M

Total Liabilities

$351M

Stockholders' Equity

-$19M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$48M	$38M	+26.5%
Gross Profit	$38M	$30M	+23.4%
Operating Income	-$8M	-$16M	+48.8%
Net Income	-$15M	-$20M	+24.4%

Revenue Segments

Product

$47M78%

Keveyis

$13M22%